Chemotherapy in patients with anthracycline and taxane-pretreated metastatic breast cancer

An overview

Eleni Andreopoulou, Joseph A. Sparano

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Anthracyclines and taxanes are cytotoxic agents commonly used for treatment of breast cancer, including in adjuvant, neoadjuvant, and metastatic settings. Each drug class is associated with cumulative and potentially irreversible toxicity, including cardiomyopathy (anthracyclines) and neuropathy (taxanes). This may either limit the duration of therapy for advanced disease, or prevent retreatment for recurrence if previously used as component of adjuvant or neoadjuvant therapy. Several classes of cytotoxic agent have been evaluated in patients with anthracycline and taxane-pretreated metastatic breast cancer (MBC), including other antitubulins (vinorelbine, ixabepilone, eribulin), antimetabolites (capecitabine, gemcitabine), topoisomerase I inhibitors (irinotecan), platinum analogues (cisplatin, carboplatin), and liposomal doxorubicin preparations. No trials have shown an overall survival advantage for combination chemotherapy in this setting, indicating that single cytotoxic agents should usually be used, expect perhaps for patients with rapidly progressive disease and/or high tumor burden.

Original languageEnglish (US)
Pages (from-to)42-50
Number of pages9
JournalCurrent Breast Cancer Reports
Volume5
Issue number1
DOIs
StatePublished - Mar 2013

Fingerprint

Anthracyclines
Cytotoxins
Taxoids
irinotecan
eribulin
Breast Neoplasms
gemcitabine
Drug Therapy
Topoisomerase I Inhibitors
Antimetabolites
Retreatment
Neoadjuvant Therapy
Carboplatin
Combination Drug Therapy
Platinum
Tumor Burden
Cardiomyopathies
Cisplatin
Recurrence
Survival

Keywords

  • Anthracycline
  • Chemotherapy
  • Cytotoxic agents
  • Drug resistance
  • MBC
  • Metastatic breast cancer
  • Pretreated
  • Systemic cytotoxic therapy
  • Taxane

ASJC Scopus subject areas

  • Oncology

Cite this

Chemotherapy in patients with anthracycline and taxane-pretreated metastatic breast cancer : An overview. / Andreopoulou, Eleni; Sparano, Joseph A.

In: Current Breast Cancer Reports, Vol. 5, No. 1, 03.2013, p. 42-50.

Research output: Contribution to journalArticle

@article{efa51aa3f6c74e5480f3032887b39b20,
title = "Chemotherapy in patients with anthracycline and taxane-pretreated metastatic breast cancer: An overview",
abstract = "Anthracyclines and taxanes are cytotoxic agents commonly used for treatment of breast cancer, including in adjuvant, neoadjuvant, and metastatic settings. Each drug class is associated with cumulative and potentially irreversible toxicity, including cardiomyopathy (anthracyclines) and neuropathy (taxanes). This may either limit the duration of therapy for advanced disease, or prevent retreatment for recurrence if previously used as component of adjuvant or neoadjuvant therapy. Several classes of cytotoxic agent have been evaluated in patients with anthracycline and taxane-pretreated metastatic breast cancer (MBC), including other antitubulins (vinorelbine, ixabepilone, eribulin), antimetabolites (capecitabine, gemcitabine), topoisomerase I inhibitors (irinotecan), platinum analogues (cisplatin, carboplatin), and liposomal doxorubicin preparations. No trials have shown an overall survival advantage for combination chemotherapy in this setting, indicating that single cytotoxic agents should usually be used, expect perhaps for patients with rapidly progressive disease and/or high tumor burden.",
keywords = "Anthracycline, Chemotherapy, Cytotoxic agents, Drug resistance, MBC, Metastatic breast cancer, Pretreated, Systemic cytotoxic therapy, Taxane",
author = "Eleni Andreopoulou and Sparano, {Joseph A.}",
year = "2013",
month = "3",
doi = "10.1007/s12609-012-0097-1",
language = "English (US)",
volume = "5",
pages = "42--50",
journal = "Current Breast Cancer Reports",
issn = "1943-4588",
publisher = "Current Science, Inc.",
number = "1",

}

TY - JOUR

T1 - Chemotherapy in patients with anthracycline and taxane-pretreated metastatic breast cancer

T2 - An overview

AU - Andreopoulou, Eleni

AU - Sparano, Joseph A.

PY - 2013/3

Y1 - 2013/3

N2 - Anthracyclines and taxanes are cytotoxic agents commonly used for treatment of breast cancer, including in adjuvant, neoadjuvant, and metastatic settings. Each drug class is associated with cumulative and potentially irreversible toxicity, including cardiomyopathy (anthracyclines) and neuropathy (taxanes). This may either limit the duration of therapy for advanced disease, or prevent retreatment for recurrence if previously used as component of adjuvant or neoadjuvant therapy. Several classes of cytotoxic agent have been evaluated in patients with anthracycline and taxane-pretreated metastatic breast cancer (MBC), including other antitubulins (vinorelbine, ixabepilone, eribulin), antimetabolites (capecitabine, gemcitabine), topoisomerase I inhibitors (irinotecan), platinum analogues (cisplatin, carboplatin), and liposomal doxorubicin preparations. No trials have shown an overall survival advantage for combination chemotherapy in this setting, indicating that single cytotoxic agents should usually be used, expect perhaps for patients with rapidly progressive disease and/or high tumor burden.

AB - Anthracyclines and taxanes are cytotoxic agents commonly used for treatment of breast cancer, including in adjuvant, neoadjuvant, and metastatic settings. Each drug class is associated with cumulative and potentially irreversible toxicity, including cardiomyopathy (anthracyclines) and neuropathy (taxanes). This may either limit the duration of therapy for advanced disease, or prevent retreatment for recurrence if previously used as component of adjuvant or neoadjuvant therapy. Several classes of cytotoxic agent have been evaluated in patients with anthracycline and taxane-pretreated metastatic breast cancer (MBC), including other antitubulins (vinorelbine, ixabepilone, eribulin), antimetabolites (capecitabine, gemcitabine), topoisomerase I inhibitors (irinotecan), platinum analogues (cisplatin, carboplatin), and liposomal doxorubicin preparations. No trials have shown an overall survival advantage for combination chemotherapy in this setting, indicating that single cytotoxic agents should usually be used, expect perhaps for patients with rapidly progressive disease and/or high tumor burden.

KW - Anthracycline

KW - Chemotherapy

KW - Cytotoxic agents

KW - Drug resistance

KW - MBC

KW - Metastatic breast cancer

KW - Pretreated

KW - Systemic cytotoxic therapy

KW - Taxane

UR - http://www.scopus.com/inward/record.url?scp=84873455707&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873455707&partnerID=8YFLogxK

U2 - 10.1007/s12609-012-0097-1

DO - 10.1007/s12609-012-0097-1

M3 - Article

VL - 5

SP - 42

EP - 50

JO - Current Breast Cancer Reports

JF - Current Breast Cancer Reports

SN - 1943-4588

IS - 1

ER -